RSK3 switches cell fate: from stress-induced senescence to malignant progression.
Breast tumor
Cellular senescence
Epithelial-mesenchymal transition
TGFβ
Journal
Journal of experimental & clinical cancer research : CR
ISSN: 1756-9966
Titre abrégé: J Exp Clin Cancer Res
Pays: England
ID NLM: 8308647
Informations de publication
Date de publication:
27 Nov 2023
27 Nov 2023
Historique:
received:
22
06
2023
accepted:
19
11
2023
medline:
28
11
2023
pubmed:
27
11
2023
entrez:
26
11
2023
Statut:
epublish
Résumé
TGFβ induces several cell phenotypes including senescence, a stable cell cycle arrest accompanied by a secretory program, and epithelial-mesenchymal transition (EMT) in normal epithelial cells. During carcinogenesis cells lose the ability to undergo senescence in response to TGFβ but they maintain an EMT, which can contribute to tumor progression. Our aim was to identify mechanisms promoting TGFβ-induced senescence escape. In vitro experiments were performed with primary human mammary epithelial cells (HMEC) immortalized by hTert. For kinase library screen and modulation of gene expression retroviral transduction was used. To characterize gene expression, RNA microarray with GSEA analysis and RT-qPCR were used. For protein level and localization, Western blot and immunofluorescence were performed. For senescence characterization crystal violet assay, Senescence Associated-β-Galactosidase activity, EdU staining were conducted. To determine RSK3 partners FLAG-baited immunoprecipitation and mass spectrometry-based proteomic analyses were performed. Proteosome activity and proteasome enrichment assays were performed. To validate the role of RSK3 in human breast cancer, analysis of METABRIC database was performed. Murine intraductal xenografts using MCF10DCIS.com cells were carried out, with histological and immunofluorescence analysis of mouse tissue sections. A screen with active kinases in HMECs upon TGFβ treatment identified that the serine threonine kinase RSK3, or RPS6KA2, a kinase mainly known to regulate cancer cell death including in breast cancer, reverted TGFβ-induced senescence. Interestingly, RSK3 expression decreased in response to TGFβ in a SMAD3-dependent manner, and its constitutive expression rescued SMAD3-induced senescence, indicating that a decrease in RSK3 itself contributes to TGFβ-induced senescence. Using transcriptomic analyses and affinity purification coupled to mass spectrometry-based proteomics, we unveiled that RSK3 regulates senescence by inhibiting the NF-κΒ pathway through the decrease in proteasome-mediated IκBα degradation. Strikingly, senescent TGFβ-treated HMECs display features of epithelial to mesenchymal transition (EMT) and during RSK3-induced senescence escaped HMECs conserve EMT features. Importantly, RSK3 expression is correlated with EMT and invasion, and inversely correlated with senescence and NF-κΒ in human claudin-low breast tumors and its expression enhances the formation of breast invasive tumors in the mouse mammary gland. We conclude that RSK3 switches cell fate from senescence to malignancy in response to TGFβ signaling.
Sections du résumé
BACKGROUND
BACKGROUND
TGFβ induces several cell phenotypes including senescence, a stable cell cycle arrest accompanied by a secretory program, and epithelial-mesenchymal transition (EMT) in normal epithelial cells. During carcinogenesis cells lose the ability to undergo senescence in response to TGFβ but they maintain an EMT, which can contribute to tumor progression. Our aim was to identify mechanisms promoting TGFβ-induced senescence escape.
METHODS
METHODS
In vitro experiments were performed with primary human mammary epithelial cells (HMEC) immortalized by hTert. For kinase library screen and modulation of gene expression retroviral transduction was used. To characterize gene expression, RNA microarray with GSEA analysis and RT-qPCR were used. For protein level and localization, Western blot and immunofluorescence were performed. For senescence characterization crystal violet assay, Senescence Associated-β-Galactosidase activity, EdU staining were conducted. To determine RSK3 partners FLAG-baited immunoprecipitation and mass spectrometry-based proteomic analyses were performed. Proteosome activity and proteasome enrichment assays were performed. To validate the role of RSK3 in human breast cancer, analysis of METABRIC database was performed. Murine intraductal xenografts using MCF10DCIS.com cells were carried out, with histological and immunofluorescence analysis of mouse tissue sections.
RESULTS
RESULTS
A screen with active kinases in HMECs upon TGFβ treatment identified that the serine threonine kinase RSK3, or RPS6KA2, a kinase mainly known to regulate cancer cell death including in breast cancer, reverted TGFβ-induced senescence. Interestingly, RSK3 expression decreased in response to TGFβ in a SMAD3-dependent manner, and its constitutive expression rescued SMAD3-induced senescence, indicating that a decrease in RSK3 itself contributes to TGFβ-induced senescence. Using transcriptomic analyses and affinity purification coupled to mass spectrometry-based proteomics, we unveiled that RSK3 regulates senescence by inhibiting the NF-κΒ pathway through the decrease in proteasome-mediated IκBα degradation. Strikingly, senescent TGFβ-treated HMECs display features of epithelial to mesenchymal transition (EMT) and during RSK3-induced senescence escaped HMECs conserve EMT features. Importantly, RSK3 expression is correlated with EMT and invasion, and inversely correlated with senescence and NF-κΒ in human claudin-low breast tumors and its expression enhances the formation of breast invasive tumors in the mouse mammary gland.
CONCLUSIONS
CONCLUSIONS
We conclude that RSK3 switches cell fate from senescence to malignancy in response to TGFβ signaling.
Identifiants
pubmed: 38008756
doi: 10.1186/s13046-023-02909-5
pii: 10.1186/s13046-023-02909-5
pmc: PMC10680185
doi:
Substances chimiques
Proteasome Endopeptidase Complex
EC 3.4.25.1
Transforming Growth Factor beta
0
ribosomal protein S6 kinase, 90kDa, polypeptide 3
EC 2.7.11.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
318Subventions
Organisme : Institut National Du Cancer
ID : PLBio 18-144
Organisme : Institut National Du Cancer
ID : PLBio 15-013
Informations de copyright
© 2023. The Author(s).
Références
Curr Biol. 2000 Feb 10;10(3):127-35
pubmed: 10679322
J Cell Biol. 1994 Dec;127(6 Pt 2):2021-36
pubmed: 7806579
Neoplasia. 2013 Dec;15(12):1354-62
pubmed: 24403857
Aging (Albany NY). 2015 Nov;7(11):986-1003
pubmed: 26583757
Nucleic Acids Res. 2022 Jan 7;50(D1):D543-D552
pubmed: 34723319
Nature. 2013 Jul 4;499(7456):97-101
pubmed: 23803760
Oncogene. 2012 Jun 28;31(26):3148-63
pubmed: 22020330
Breast Cancer Res. 2009;11(5):R66
pubmed: 19735549
In Vitro Cell Dev Biol. 1989 Aug;25(8):705-13
pubmed: 2548988
Cell Death Discov. 2022 Feb 26;8(1):84
pubmed: 35217648
Exp Cell Res. 2007 Aug 15;313(14):3046-56
pubmed: 17560572
Int J Mol Sci. 2019 Jun 05;20(11):
pubmed: 31195692
Semin Cancer Biol. 2018 Feb;48:53-61
pubmed: 28476656
Cell. 2019 Oct 31;179(4):813-827
pubmed: 31675495
Sci Rep. 2016 Oct 27;6:36134
pubmed: 27786305
Nucleic Acids Res. 2022 Jul 5;50(W1):W216-W221
pubmed: 35325185
Science. 1995 Mar 10;267(5203):1485-8
pubmed: 7878466
Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14723-8
pubmed: 9843956
Trends Cell Biol. 2019 Mar;29(3):212-226
pubmed: 30594349
Nat Rev Clin Oncol. 2022 Oct;19(10):619-636
pubmed: 36045302
Cancer Metastasis Rev. 2016 Dec;35(4):645-654
pubmed: 27878502
Oncogene. 2016 Jan 21;35(3):344-57
pubmed: 25893299
Cell Cycle. 2017 Feb 16;16(4):319-334
pubmed: 27892764
Clin Cancer Res. 2016 Feb 1;22(3):609-20
pubmed: 26420858
Anal Chem. 2020 Nov 17;92(22):14898-14906
pubmed: 32970414
Mol Cell Biol. 2003 Jul;23(14):4796-804
pubmed: 12832467
Genes Dev. 1992 Oct;6(10):1899-913
pubmed: 1340770
J Cell Biol. 2000 May 1;149(3):667-82
pubmed: 10791980
JCI Insight. 2023 Mar 8;8(5):
pubmed: 36883564
Nat Rev Cancer. 2016 Feb;16(2):83-98
pubmed: 26822576
Breast Cancer Res. 2010;12(5):R68
pubmed: 20813035
Nucleic Acids Res. 2010 Jun;38(11):e120
pubmed: 20215436
Nat Cell Biol. 2016 Sep;18(9):979-92
pubmed: 27525720
PLoS Biol. 2008 Dec 2;6(12):2853-68
pubmed: 19053174
Cancers (Basel). 2021 Jun 14;13(12):
pubmed: 34198590
Proteomics. 2013 Aug;13(16):2419-23
pubmed: 23744604
Nat Commun. 2020 Jun 1;11(1):2711
pubmed: 32483135
Biomolecules. 2020 Mar 23;10(3):
pubmed: 32210029
Proc Natl Acad Sci U S A. 2011 May 24;108(21):8668-73
pubmed: 21555587
Cancer Res. 2004 Jan 15;64(2):472-81
pubmed: 14744759
Cell. 2007 Jun 15;129(6):1065-79
pubmed: 17574021
Genes Dev. 2020 Dec 1;34(23-24):1565-1576
pubmed: 33262144
Cold Spring Harb Perspect Biol. 2017 Apr 3;9(4):
pubmed: 27920038
Cell. 2008 Jun 13;133(6):1006-18
pubmed: 18555777
Cancer Res. 2003 Jul 1;63(13):3447-52
pubmed: 12839923
Cytokine. 2019 May;117:15-22
pubmed: 30776684
Cancer Res. 2011 Feb 1;71(3):998-1008
pubmed: 21245094
Cancer Res. 2013 Sep 1;73(17):5301-8
pubmed: 23970478
Nucleic Acids Res. 2018 Oct 12;46(18):9578-9590
pubmed: 30137431
J Clin Invest. 2013 Jun;123(6):2551-63
pubmed: 23635776
J Anat. 2020 Jul;237(1):29-47
pubmed: 32162697
Nature. 2006 Nov 30;444(7119):633-7
pubmed: 17136093
Annu Rev Immunol. 2000;18:621-63
pubmed: 10837071
J Neurosci. 2004 May 5;24(18):4324-32
pubmed: 15128846
Cell. 2021 Sep 30;184(20):5230-5246.e22
pubmed: 34551315
Bioinformatics. 2020 May 1;36(10):3148-3155
pubmed: 32096818
Biochem Biophys Res Commun. 2010 Sep 3;399(4):659-64
pubmed: 20691661
Signal Transduct Target Ther. 2017;2:
pubmed: 29158945
Proc Natl Acad Sci U S A. 1995 Nov 7;92(23):10599-603
pubmed: 7479848
Expert Opin Ther Targets. 2011 Jan;15(1):5-9
pubmed: 20958120
Eur J Med Chem. 2023 May 5;251:115229
pubmed: 36898330
Nature. 2012 Apr 18;486(7403):346-52
pubmed: 22522925
Curr Opin Cell Biol. 2008 Apr;20(2):150-5
pubmed: 18353625